In part 1 of this 4 part series, Michael Thorpy, MD, talks about salt intake and how health guidelines and individual habits shape what kind of medication is right for patients with sleep disorders like excessive daytime sleepiness or narcolepsy.
Readers can also check out part 2 now.
Understanding existing patient sodium intake and medication availability is key in prescribing medications to patients with sleep disorders like excessive daytime sleepiness or narcolepsy, explains Michael Thorpy, MD, professor of neurology at the Albert Einstein College of Medicine, and director of the Sleep Disorder Center at Montefiore Medical Center.
Transcript
Why is it important to consider low-sodium sleep medications and salt/sodium intake with therapeutics and not only food for patients with sleep disorders?
There's an increasing awareness about the importance of salts in our diets. It seems as though every few years there are recommendations that are made about limiting the amount of salt intake that we take. At the present time, the American Heart Association recommends that people should only ingest about 2300 mg of salt a day. Ideally, it should be even less than that at 1500 mg.
However, some of the medications do have a fairly high salt content, and the one that's of particular concern in sleep medicine is the salt content of a medication that's used for the treatment of narcolepsy and other disorders of excessive daytime sleepiness. There is a formulation called sodium oxybate, which at the highest recommended dose contains 1940 mg of salt, or sodium. It is estimated that the average intake of salt in the United States is 3400 mg a day. If somebody is taking the maximum dose of sodium oxybate, then they're getting probably over 5000 mg of salt a day. That amount of salt seems to be somewhat excessive.
So, there is some concern about that, and new formulations of the sodium oxybate have been developed that have a much lower sodium content, so as to prevent people from having an excessive amount of salt intake.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More